N
Nataliya L. Voytko
Publications - 7
Citations - 2023
Nataliya L. Voytko is an academic researcher. The author has contributed to research in topics: Letrozole & Palbociclib. The author has an hindex of 6, co-authored 7 publications receiving 1799 citations.
Papers
More filters
Journal ArticleDOI
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn,John Crown,István Láng,Katalin Boér,Igor Bondarenko,Sergey O. Kulyk,Johannes Ettl,Ravindranath Patel,Tamás Pintér,Marcus Schmidt,Yaroslav Shparyk,Anu Thummala,Nataliya L. Voytko,Camilla Fowst,Xin Huang,Sindy T. Kim,Sophia Randolph,Dennis J. Slamon +17 more
TL;DR: Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of growth-inhibitory activity in oestrogen receptor-positive breast cancer cells and synergy with anti-oestrogens as mentioned in this paper.
Journal ArticleDOI
First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
Jonas Bergh,Igor Bondarenko,Mikhail Lichinitser,Annelie Liljegren,Richard Greil,Nataliya L. Voytko,A. Makhson,Javier Cortes,Alain Lortholary,Joachim Bischoff,Arlene Chan,Suzette Delaloge,Xin Huang,Kenneth A. Kern,Carla Giorgetti +14 more
TL;DR: The combination of sunitinib plus docetaxel improved ORR but did not prolong either PFS or OS compared with docetAXel alone when given to an unselected HER2/neu-negative cohort as first-line treatment for ABC.
Proceedings ArticleDOI
Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)
Richard S. Finn,John Crown,István Láng,Katalin Boér,I. Bondarenko,Sergey O. Kulyk,Johannes Ettl,Ravindranath Patel,Tamás Pintér,Maike Schmidt,Yaroslav Shparyk,Anu Thummala,Nataliya L. Voytko,A Breazna,Sinil Kim,Sophia Randolph,DJ Slamon +16 more
TL;DR: The combination of PD 0 332991 and letrozole is well tolerated and shows encouraging clinical benefit, confirming the sensitivity of ER+ BC to PD 0332991 observed in preclinical models.
Journal ArticleDOI
Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18).
Richard S. Finn,John Crown,István Láng,Katalin Boér,Igor Bondarenko,Sergey O. Kulyk,Johannes Ettl,Ravindranath Patel,Tamás Pintér,Marcus Schmidt,Yaroslav Shparyk,Anu Thummala,Nataliya L. Voytko,Camilla Fowst,Xin Huang,Sindy T. Kim,Dennis J. Slamon +16 more
TL;DR: PALOMA-1 was an open-label phase II trial comparing progression-free survival (PFS) in patients with advanced ER+/HER2– BC treated with P+L or L alone, with an acceptable safety profile, leading to accelerated approval by the US FDA.
Proceedings ArticleDOI
Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)
Richard S. Finn,John Crown,István Láng,Katalin Boér,Igor Bondarenko,Sergey O. Kulyk,Johannes Ettl,Ravindranath Patel,Tamás Pintér,Marcus Schmidt,Yaroslav Shparyk,Anu Thummala,Nataliya L. Voytko,Xin Huang,Sindy T. Kim,Sophia Randolph,Dennis J. Slamon +16 more
TL;DR: P+L demonstrated a statistically significant improvement in PFS and showed significant clinical benefit as first-line treatment of ER+/HER2- advanced BC in post-menopausal women.